前立腺の健康市場

出版:MarketsandMarkets(マーケッツアンドマーケッツ) 出版年月:2021年12月

前立腺の健康市場: 疾患の適応症(前立腺癌、PARP阻害剤、細胞毒性薬、良性前立腺肥大症(BPH)、タムスロシン、5アルファレダクターゼ、前立腺炎、OTC、処方(Rx)、地域(北米、ヨーロッパ、APAC)- 2026年までの世界予測

Prostate Health Market by Disease Indication (Prostate Cancer, PARP Inhibitors, Cytotoxic Drug, Benign Prostate Hyperplasia (BPH), Tamsulosin, 5 Alpha Reductase, Prostatitis, OTC, Prescription (Rx), & Region (NA, Europe, APAC) – Global Forecasts to 2026

ページ数95
図表数135
種別英文調査報告書
価格

レポート目次    見積ご依頼・お問合せ    ご購入案内

無料サンプル

The global prostate health market is projected to reach USD 48.9 billion by 2026 from USD 31.8 billion in 2021, at a CAGR of 9.0% during the forecast period. The prostate gland (the prostate) is an organ of the male reproductive system. The three most common forms of prostate disease are inflammation (prostatitis), non-cancerous enlargement of the prostate (benign prostatic hyperplasia or BPH), and prostate cancer. Benign prostatic hyperplasia (BPH) is defined as a medical condition affecting men. It involves the non-cancerous enlargement of the prostate gland. While BPH rarely shows symptoms before the age of 40, the risk of contracting BPH increases with age. The condition affects nearly 50% of men between the ages of 51 and 60 and up to 90% of men older than 80. Treatment measures such as medications and surgery have been used for patients with BPH.

Prostate Cancerto hold thelargestsegmentof the market
Based on disease indication, the prostate health market is segmented into prostate cancer, benign prostate hyperplasia, and prostatitis. In 2020, prostate cancer accounted for the largest share in the prostate health market. Typically, hormone therapy is considered an effective option as the first line of treatment for prostate cancer. Cancer vaccines, radiopharmaceutical agents, secondary hormone therapies, or chemotherapies follow hormonal therapy as treatment options. Cancerous cells are found to be developing a resistance to these therapies after some months, as a result of which immunotherapies are expected to be adopted widely for the treatment of prostate cancer in the near future.

The US to dominate theprostate health market in North America
The prostate health market is segmented into five six regions—North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America has been among the frontrunners in developing prostate health therapiesin the healthcare industry. The market growth in the US (a major contributor to the North American prostate health market) can be mainly attributed to the growing target population, the high incidence of BPH, prostate cancer, and prostatitis, and the strong presence of medical device manufacturers. Additionally, favorable reimbursement policies, high disposable incomes, a strong healthcare infrastructure, research funding, and product launches have accelerated the growth of this market.

Breakdown of supply-side primary interviews: • By Company Type: Tier 1 – 20%, Tier 2 – 45%, and Tier 3 – 35% • By Designation:Director-level – 30%, C-level – 20%, and Others – 50% • By Region: North America – 33%, Europe – 24%, APAC –27%, Rest of the World –16%
Some of the prominent players operating in the prostate healthmarket are Eli Lilly and Company (US), Pfizer Inc. (US), Merck & Co., Inc. (US), GlaxoSmithKline plc. (UK), Abbott (US), and Astellas Pharma Inc. (Japan) and other players.

Research Coverage
This report studies the prostate health market based on type, mode of purchase, and application, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to two main geographies – source and destination.

Key Benefits of Buying the Report
This report focuses on various levels of analysis—industry trends, market share of top players, and company profiles, which together form basic views and analyze the competitive landscape, and high-growth regions and their drivers, restraints, challenges, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.


目次

1INTRODUCTION17
1.1OBJECTIVES OF THE STUDY17
1.2MARKET DEFINITION17
1.2.1INCLUSIONS & EXCLUSIONS OF THE STUDY18
1.3MARKET SCOPE19
1.3.1MARKETS COVERED19
1.3.2YEARS CONSIDERED FOR THE STUDY19
1.4CURRENCY20
1.5STAKEHOLDERS20
1.6LIMITATIONS OF THE CURRENT EDITION OF THE REPORT20
2RESEARCH METHODOLOGY21
2.1RESEARCH DATA21
FIGURE 1RESEARCH DESIGN21
2.1.1SECONDARY DATA22
2.1.1.1Key data from secondary sources22
2.1.2PRIMARY DATA23
FIGURE 2BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION23
2.1.2.1Key data from primary sources23
2.2MARKET SIZE ESTIMATION24
FIGURE 3RESEARCH METHODOLOGY: HYPOTHESIS BUILDING24
2.2.1BOTTOM-UP APPROACH25
2.2.2GROWTH FORECAST25
2.2.3TOP-DOWN APPROACH25
FIGURE 4PROSTATE HEALTH MARKET: TOP-DOWN APPROACH25
2.3MARKET BREAKDOWN AND DATA TRIANGULATION26
FIGURE 5DATA TRIANGULATION METHODOLOGY26
2.4ASSUMPTIONS FOR THE STUDY27
3MARKET DYNAMICS28
3.1MARKET DYNAMICS28
FIGURE 6PROSTATE HEALTH MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES28
3.1.1DRIVERS29
3.1.1.1Increasing prevalence of benign prostatic hyperplasia29
FIGURE 7SHARE OF THE MALE POPULATION AGED 65 AND ABOVE, GLOBAL
(2015-2019)29
3.1.1.2Increasing obesity29
3.1.1.3Investments, funds, and grants for research in BPH treatment30
3.1.1.4Rising prevalence of prostate cancer30
3.1.1.5Increasing demand for hormone therapy drugs30
3.1.1.6Emerging therapies for prostate cancer31
TABLE 1SELECT THERAPIES IN THE PHASE III PIPELINE FOR PROSTATE CANCER31
3.1.2RESTRAINTS31
3.1.2.1Side-effects associated with BPH medications31
TABLE 2SIDE-EFFECTS OF BPH DRUGS32
3.1.3OPPORTUNITIES32
3.1.3.1Emerging markets32
3.1.3.2Promising product pipeline33
TABLE 3PIPELINE DRUGS33
3.1.4CHALLENGES33
3.1.4.1Low awareness regarding prostate health among men33
3.1.4.2Product recalls in the prostate health market33
TABLE 4PRODUCT RECALLS IN THE PROSTATE HEALTH MARKET34
4PROSTATE HEALTH MARKET, BY DISEASE TYPE35
4.1INTRODUCTION36
TABLE 5PROSTATE HEALTH MARKET, BY DISEASE TYPE, 2018–2026 (USD MILLION)36
4.2PROSTATE CANCER36
TABLE 6PROSTATE CANCER MARKET, BY PRODUCT, 2018–2026 (USD MILLION)36
TABLE 7PROSTATE CANCER MARKET, BY REGION, 2018–2026 (USD MILLION)37
4.2.1AR-DIRECTED THERAPIES37
4.2.1.1AR-directed therapies are expected to remain the dominant drug class for the treatment of prostate cancer37
TABLE 8AR-DIRECTED THERAPIES MARKET, BY REGION, 2018–2026 (USD MILLION)37
4.2.2HORMONE ADT38
4.2.2.1ADT is the most common form of hormonal treatment38
TABLE 9HORMONAL ADT MARKET, BY REGION, 2018–2026 (USD MILLION)38
4.2.3CYTOTOXIC AGENTS38
4.2.3.1Newer cytotoxic agents are being studied in prostate cancer with the goal of achieving FDA approvals38
TABLE 10CYTOTOXIC AGENTS MARKET, BY REGION, 2018–2026 (USD MILLION)38
4.2.4POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS39
4.2.4.1PARP inhibitors are expected to be the leading drug class for the treatment of prostate cancer39
TABLE 11PARP INHIBITORS MARKET, BY REGION, 2018–2026 (USD MILLION)39
4.2.5OTHER THERAPIES39
TABLE 12OTHER THERAPIES MARKET, BY REGION, 2018–2026 (USD MILLION)39
4.3BENIGN PROSTATIC HYPERPLASIA40
TABLE 13BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)40
TABLE 14BPH DRUG TREATMENT MARKET, BY REGION, 2018–2026 (USD MILLION)40
4.3.1ALPHA BLOCKERS41
TABLE 15BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE,
2018–2026 (USD MILLION)41
TABLE 16BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY REGION,
2018–2026 (USD MILLION)41
4.3.1.1Tamsulosin42
4.3.1.1.1Tamsulosin has been prescribed for BPH since 200042
TABLE 17TAMSULOSIN MARKET, BY REGION, 2018–2026 (USD MILLION)42
4.3.1.2Silodosin42
4.3.1.2.1Benefits of silodosin and the launch of generics to support market growth42
TABLE 18SILODOSIN MARKET, BY REGION, 2018–2026 (USD MILLION)43
4.3.1.3Alfuzosin43
4.3.1.3.1Side-effects and fewer generic launches have hindered market growth to some extent43
TABLE 19ALFUZOSIN MARKET, BY REGION, 2018–2026 (USD MILLION)43
4.3.1.4Doxazosin44
4.3.1.4.1Doxazosin was introduced in 2005 and has seen many generic launches since44
TABLE 20DOXAZOSIN MARKET, BY REGION, 2018–2026 (USD MILLION)44
4.3.1.5Other alpha blockers44
TABLE 21OTHER ALPHA BLOCKERS MARKET, BY REGION, 2018–2026 (USD MILLION)45
4.3.25-ALPHA REDUCTASE INHIBITORS45
TABLE 22BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE,
2018–2026 (USD MILLION)45
TABLE 23BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY REGION,
2018–2026 (USD MILLION)46
4.3.2.1Dutasteride46
4.3.2.1.1Availability of generics post-patent expiry to support market growth46
TABLE 24DUTASTERIDE MARKET, BY REGION, 2018–2026 (USD MILLION)46
4.3.2.2Finasteride47
4.3.2.2.1Finasteride is less effective than alpha blockers in improving LUTS47
TABLE 25FINASTERIDE MARKET, BY REGION, 2018–2026 (USD MILLION)47
4.3.3OTHER DRUG CLASSES47
TABLE 26OTHER BPH DRUG CLASSES MARKET, BY REGION,
2018–2026 (USD MILLION)48
4.4PROSTATITIS48
TABLE 27PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION)48
TABLE 28PROSTATITIS MARKET, BY REGION, 2018–2026 (USD MILLION)48
4.4.1PRESCRIPTION PRODUCTS49
4.4.1.1Prescription drugs account for the larger share of the products used for the treatment of prostatitis49
TABLE 29PRESCRIPTION PRODUCTS MARKET, BY REGION, 2018–2026 (USD MILLION)49
4.4.2OVER-THE-COUNTER PRODUCTS49
4.4.2.1Sales of OTC products have risen over the past few years49
TABLE 30OVER-THE-COUNTER PRODUCTS MARKET, BY REGION,
2018–2026 (USD MILLION)50
5PROSTATE HEALTH MARKET, BY REGION51
5.1INTRODUCTION52
TABLE 31PROSTATE HEALTH MARKET, BY REGION, 2018–2026 (USD MILLION)52
5.2NORTH AMERICA52
TABLE 32NORTH AMERICA: PROSTATE HEALTH MARKET, BY COUNTRY,
2018–2026 (USD MILLION)53
TABLE 33NORTH AMERICA: PROSTATE HEALTH MARKET, BY DISEASE TYPE,
2018–2026 (USD MILLION)53
TABLE 34NORTH AMERICA: PROSTATE CANCER MARKET, BY PRODUCT,
2018–2026 (USD MILLION)53
TABLE 35NORTH AMERICA: BPH DRUG TREATMENT MARKET, BY CLASS,
2018–2026 (USD MILLION)54
TABLE 36NORTH AMERICA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)54
TABLE 37NORTH AMERICA: BPH DRUG TREATMENT MARKET FOR 5-ARIS,
BY TYPE, 2018–2026 (USD MILLION)54
TABLE 38NORTH AMERICA: PROSTATITIS MARKET, BY PRODUCT,
2018–2026 (USD MILLION)55
5.2.1US55
5.2.1.1The US holds the largest share of the North American market55
TABLE 39US: PROSTATE HEALTH MARKET, BY DISEASE TYPE,
2018–2026 (USD MILLION)55
TABLE 40US: PROSTATE CANCER MARKET, BY PRODUCT, 2018–2026 (USD MILLION)56
TABLE 41US: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)56
TABLE 42US: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE,
2018–2026 (USD MILLION)56
TABLE 43US: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE,
2018–2026 (USD MILLION)57
TABLE 44US: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION)57
5.2.2CANADA57
5.2.2.1Rising geriatric population and product approvals to support market growth57
TABLE 45CANADA: PROSTATE HEALTH MARKET, BY DISEASE TYPE,
2018–2026 (USD MILLION)58
TABLE 46CANADA: PROSTATE CANCER MARKET, BY PRODUCT,
2018–2026 (USD MILLION)58
TABLE 47CANADA: BPH DRUG TREATMENT MARKET, BY CLASS,
2018–2026 (USD MILLION)58
TABLE 48CANADA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS,
BY TYPE, 2018–2026 (USD MILLION)59
TABLE 49CANADA: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE,
2018–2026 (USD MILLION)59
TABLE 50CANADA: PROSTATITIS MARKET, BY PRODUCT,
2018–2026 (USD MILLION)59
5.3EUROPE60
TABLE 51EUROPE: PROSTATE HEALTH MARKET, BY DISEASE TYPE,
2018–2026 (USD MILLION)60
TABLE 52EUROPE: PROSTATE CANCER MARKET, BY PRODUCT,
2018–2026 (USD MILLION)60
TABLE 53EUROPE: BPH DRUG TREATMENT MARKET, BY CLASS,
2018–2026 (USD MILLION)60
TABLE 54EUROPE: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)61
TABLE 55EUROPE: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE,
2018–2026 (USD MILLION)61
TABLE 56EUROPE: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION)61
TABLE 57EUROPE: PROSTATE HEALTH MARKET, BY COUNTRY,
2018–2026 (USD MILLION)62
5.3.1GERMANY62
5.3.1.1Increasing healthcare expenditure to support German market growth62
TABLE 58GERMANY: PROSTATE HEALTH MARKET, BY DISEASE TYPE,
2018–2026 (USD MILLION)62
TABLE 59GERMANY: PROSTATE CANCER MARKET, BY PRODUCT,
2018–2026 (USD MILLION)63
TABLE 60GERMANY: BPH DRUG TREATMENT MARKET, BY CLASS,
2018–2026 (USD MILLION)63
TABLE 61GERMANY: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS,
BY TYPE, 2018–2026 (USD MILLION)63
TABLE 62GERMANY: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE,
2018–2026 (USD MILLION)64
TABLE 63GERMANY: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION)64
5.3.2UK64
5.3.2.1Availability of innovative treatment options to drive the market in
the UK64
TABLE 64UK: PROSTATE HEALTH MARKET, BY DISEASE TYPE,
2018–2026 (USD MILLION)65
TABLE 65UK: PROSTATE CANCER MARKET, BY PRODUCT, 2018–2026 (USD MILLION)65
TABLE 66UK: BPH DRUG TREATMENT MARKET, BY CLASS, 2018–2026 (USD MILLION)65
TABLE 67UK: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE,
2018–2026 (USD MILLION)66
TABLE 68UK: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE,
2018–2026 (USD MILLION)66
TABLE 69UK: PROSTATITIS MARKET, BY PRODUCT,
2018–2026 (USD MILLION)66
5.3.3FRANCE67
5.3.3.1Rising geriatric population to accelerate the growth of the market67
TABLE 70FRANCE: PROSTATE HEALTH MARKET, BY DISEASE TYPE,
2018–2026 (USD MILLION)67

TABLE 71FRANCE: PROSTATE CANCER MARKET, BY PRODUCT,
2018–2026 (USD MILLION)67
TABLE 72FRANCE: BPH DRUG TREATMENT MARKET, BY CLASS,
2018–2026 (USD MILLION)68
TABLE 73FRANCE: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS,
BY TYPE, 2018–2026 (USD MILLION)68
TABLE 74FRANCE: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE,
2018–2026 (USD MILLION)68
TABLE 75FRANCE: PROSTATITIS MARKET, BY PRODUCT,
2018–2026 (USD MILLION)69
5.3.4REST OF EUROPE69
TABLE 76ROE: PROSTATE HEALTH MARKET, BY DISEASE TYPE,
2018–2026 (USD MILLION)69
TABLE 77ROE: PROSTATE CANCER MARKET, BY PRODUCT, 2018–2026 (USD MILLION)70
TABLE 78ROE: BPH DRUG TREATMENT MARKET, BY CLASS,
2018–2026 (USD MILLION)70
TABLE 79ROE: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS,
BY TYPE, 2018–2026 (USD MILLION)70
TABLE 80ROE: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE,
2018–2026 (USD MILLION)71
TABLE 81ROE: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION)71
5.4ASIA PACIFIC71
TABLE 82ASIA PACIFIC: PROSTATE HEALTH MARKET, BY DISEASE TYPE,
2018–2026 (USD MILLION)71
TABLE 83ASIA PACIFIC: PROSTATE CANCER MARKET, BY PRODUCT,
2018–2026 (USD MILLION)72
TABLE 84ASIA PACIFIC: BPH DRUG TREATMENT MARKET, BY CLASS,
2018–2026 (USD MILLION)72
TABLE 85ASIA PACIFIC: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS,
BY TYPE, 2018–2026 (USD MILLION)72
TABLE 86ASIA PACIFIC: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE,
2018–2026 (USD MILLION)73
TABLE 87ASIA PACIFIC: PROSTATITIS MARKET, BY PRODUCT,
2018–2026 (USD MILLION)73
TABLE 88ASIA PACIFIC: PROSTATE HEALTH MARKET, BY COUNTRY,
2018–2026 (USD MILLION)73
5.4.1JAPAN74
5.4.1.1Japan holds the largest share of the APAC market74
TABLE 89JAPAN: PROSTATE HEALTH MARKET, BY DISEASE TYPE,
2018–2026 (USD MILLION)74
TABLE 90JAPAN: PROSTATE CANCER MARKET, BY PRODUCT,
2018–2026 (USD MILLION)75
TABLE 91JAPAN: BPH DRUG TREATMENT MARKET, BY CLASS,
2018–2026 (USD MILLION)75
TABLE 92JAPAN: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS,
BY TYPE, 2018–2026 (USD MILLION)75

TABLE 93JAPAN: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE,
2018–2026 (USD MILLION)76
TABLE 94JAPAN: PROSTATITIS MARKET, BY PRODUCT,
2018–2026 (USD MILLION)76
5.4.2CHINA76
5.4.2.1Increasing obese population to support market growth76
TABLE 95CHINA: PROSTATE HEALTH MARKET, BY DISEASE TYPE,
2018–2026 (USD MILLION)77
TABLE 96CHINA: PROSTATE CANCER MARKET, BY PRODUCT,
2018–2026 (USD MILLION)77
TABLE 97CHINA: BPH DRUG TREATMENT MARKET, BY CLASS,
2018–2026 (USD MILLION)77
TABLE 98CHINA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)78
TABLE 99CHINA: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE,
2018–2026 (USD MILLION)78
TABLE 100CHINA: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION)78
5.4.3INDIA79
5.4.3.1Rising prevalence of obesity to accelerate market growth in India79
TABLE 101INDIA: PROSTATE HEALTH MARKET, BY DISEASE TYPE,
2018–2026 (USD MILLION)79
TABLE 102INDIA: PROSTATE CANCER MARKET, BY PRODUCT,
2018–2026 (USD MILLION)79
TABLE 103INDIA: BPH DRUG TREATMENT MARKET, BY CLASS,
2018–2026 (USD MILLION)80
TABLE 104INDIA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS,
BY TYPE, 2018–2026 (USD MILLION)80
TABLE 105INDIA: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE,
2018–2026 (USD MILLION)80
TABLE 106INDIA: PROSTATITIS MARKET, BY PRODUCT,
2018–2026 (USD MILLION)80
5.4.4REST OF ASIA PACIFIC81
TABLE 107ROAPAC: PROSTATE HEALTH MARKET, BY DISEASE TYPE,
2018–2026 (USD MILLION)81
TABLE 108ROAPAC: PROSTATE CANCER MARKET, BY PRODUCT,
2018–2026 (USD MILLION)81
TABLE 109ROAPAC: BPH DRUG TREATMENT MARKET, BY CLASS,
2018–2026 (USD MILLION)82
TABLE 110ROAPAC: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)82
TABLE 111ROAPAC: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE,
2018–2026 (USD MILLION)82
TABLE 112ROAPAC: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION)83

5.5LATIN AMERICA83
5.5.1LATAM MARKETS DRIVEN BY GROWING PATIENT BASE83
TABLE 113LATAM: PROSTATE HEALTH MARKET, BY DISEASE TYPE,
2018–2026 (USD MILLION)83
TABLE 114LATAM: PROSTATE CANCER MARKET, BY PRODUCT,
2018–2026 (USD MILLION)83
TABLE 115LATAM: BPH DRUG TREATMENT MARKET, BY CLASS,
2018–2026 (USD MILLION)84
TABLE 116LATAM: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)84
TABLE 117LATAM: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE,
2018–2026 (USD MILLION)84
TABLE 118LATAM: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION)84
5.6MIDDLE EAST AND AFRICA85
5.6.1MEA COUNTRIES HOLD SMALLEST SHARE OF GLOBAL MARKET85
TABLE 119MEA: PROSTATE HEALTH MARKET, BY DISEASE TYPE,
2018–2026 (USD MILLION)85
TABLE 120MEA: PROSTATE CANCER MARKET, BY PRODUCT,
2018–2026 (USD MILLION)85
TABLE 121MEA: BPH DRUG TREATMENT MARKET, BY CLASS,
2018–2026 (USD MILLION)86
TABLE 122MEA: BPH DRUG TREATMENT MARKET FOR ALPHA BLOCKERS, BY TYPE, 2018–2026 (USD MILLION)86
TABLE 123MEA: BPH DRUG TREATMENT MARKET FOR 5-ARIS, BY TYPE,
2018–2026 (USD MILLION)86
TABLE 124MEA: PROSTATITIS MARKET, BY PRODUCT, 2018–2026 (USD MILLION)86
6COMPETITIVE LANDSCAPE87
6.1OVERVIEW87
6.2REVENUE ANALYSIS OF BPH TREATMENT MARKET87
6.2.1BPH MARKET REVENUE ANALYSIS OF TOP FOUR MARKET PLAYERS87
FIGURE 8TOP 5 PLAYERS HAVE DOMINATED THE MARKET IN THE LAST 3 YEARS87
6.3REVENUE ANALYSIS OF PROSTATE CANCER THERAPEUTICS MARKET88
6.3.1PROSTATE CANCER THERAPEUTICS REVENUE ANALYSIS OF TOP 5 MARKET PLAYERS88
FIGURE 9TOP 4 PLAYERS HAVE DOMINATED THE MARKET IN THE LAST 3 YEARS88
6.4MARKET SHARE ANALYSIS, 202089
6.4.1PROSTATE HEALTH MARKET SHARE ANALYSIS, 202089
FIGURE 10PROSTATE HEALTH MARKET SHARE ANALYSIS, 201989
6.5COMPANY EVALUATION MATRIX90
6.5.1STARS90
6.5.2EMERGING LEADERS90
6.5.3PERVASIVE COMPANIES90
6.5.4PARTICIPANTS90
FIGURE 11PROSTATE HEALTH MARKET: COMPANY EVALUATION MATRIX, 202091
7COMPANY PROFILES92
7.1GLAXOSMITHKLINE92
7.2ASTELLAS PHARMA92
7.3MERCK93
7.4ELI LILLY AND COMPANY93
7.5ABBOTT LABORATORIES94
7.6JOHNSON & JOHNSON SERVICES, INC.94
7.7ABBVIE95
7.8ASTRAZENECA95
7.9SANOFI96
7.10PFIZER, INC.96
8APPENDIX97
8.1KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL97
8.2AVAILABLE CUSTOMIZATIONS99
8.3AUTHOR DETAILS99


    お問合せフォーム

    • *のある項目は必須項目です。

    • レポートのタイトルは自動で入ります。

    • 無料サンプルはご購入を検討されている方向けのレポート形式等確認用資料です。
      重要記述や数値は記載されていません。予めご了承ください。

    お名前*

    会社名*

    部署名

    メールアドレス*

    電話番号

    当ウェブサイトを知った経緯を教えてください。

    お問合せ内容

    株式会社SEMABIZ・ChosaReport.com プライバシーポリシー

    Eメールでのお問合せもお受けしております。
    下記アドレスへ“(at)”を“@”に変えてお送りください。通常1営業日以内にご返信いたします。
    crinquiry(at)chosareport.com